Kornimate/medical-research-clean huggingface dataset:
effect of anesthesia techniques on quality of recovery scores in holep surgery

Conditions: HoLEP; QoR-40; Anesthesia, General; Anesthesia,Spinal; Anesthesia; Combine Spinal and Epidural

Summary: the aim of this observational study is to evaluate the effects of different anesthesia techniques on the quality of recovery (qor) and patient satisfaction in male patients, typically older adults with benign prostatic hyperplasia, undergoing holmium laser enucleation of the prostate (holep). participants will undergo holep surgery under one of three anesthesia techniques-general, spinal, or combined spinal-epidural anesthesia-and will complete the qor-40 questionnaire both before and after the surgery.

these patients will be informed about the preoperative study and the quality of recovery 40 (qor-40) scoring scale will be applied by the responsible researcher preoperatively and within 24 hours postoperatively, and the values will be recorded. the anesthesia method of the patients will be determined as determined routinely according to the patient's age, additional diseases, duration of surgery, and patient preference and will be applied by an experienced anesthesiologist. routine intraoperative follow-ups of all patients will be performed. surgeries completed without any complications will be taken to the recovery unit at the end of the procedure, and stable patients will be transferred to the ward. in patients whose ward follow-ups continue routinely, catheter-related bladder discomfort will be evaluated within 24 hours postoperatively, postoperative patient and surgeon satisfaction will be evaluated according to the 5-point likert scale, and the qor-40 score will be recorded. postoperative pain levels and analgesic needs will be recorded. parameters will be compared by dividing into groups according to the anesthesia method.

Eligibility criteria:
inclusion criteria: * patients scheduled for holep surgery due to benign prostatic hyperplasia. * patients who consent to participate in the study. exclusion criteria: * refusal to participate in the study * presence of cognitive impairment * use of psychoactive medications * failure of the intraoperative anesthesia technique and necessity to change the anesthesia method * requirement for reoperation or admission to the intensive care unit * voluntary withdrawal from the study

Keywords: holep quality of recovery (qor-40) patient satisfaction spinal anesthesia general anesthesia benign prostatic hyperplasia spinal-epidural anesthesia
pelvic and aortic-cava lymphadenectomy randomized for ovarian cancer

Conditions: Ovarian Cancer

Summary: it is a multicenter randomized trial of superior cleaning compared the absence of dissection in stage iii patients with optimal surgical resection without retroperitoneal lymph node palpable.


Eligibility criteria:
inclusion criteria: * age\> 18 years * karnofsky\> 80, or asa i-ii * primary ovarian adenocarcinoma, or primitive peritoneal * no retroperitoneal lymph node\> 2cm (ct; mri) * complete surgical staging * stage iii-iv figo classification * indication of systemic chemotherapy before surgery or post surgery exclusion criteria: * non invasive cancer * non-epithelial or borderline cancer * pregnancy * previous pelvic lymphadenectomy or aortic-cava for a disease other than ovarian cancer * contraindication to platinum and paclitaxel * borderline ovarian tumor * tumor recurrence * incomplete surgery, resectable lesion, surgery sub optimal (r\> 1cm)

Keywords: surgery ovarian cancer lymphadectomy
non-surgical treatment of periimplantitis - conventional hand instrumentation versus air-polishing

Conditions: Periimplantitis

Summary: the purpose of this study is to evaluate the clinical efficacy of ultrasonic instrumentation versus the use of an erythritol jet in the treatment of peri-implantitis.

to carry out this study, the investigators considered a treatment protocol for periimplantitis consisting of 2 phases. the first phase corresponds to the non-surgical treatment of periimplantitis, which can be performed using various techniques. in the present study, it will be carried out using manual instrumentation (with ultrasound and curettes) or with an erythritol jet. in both cases, systemic antibiotic therapy with metronidazole will be performed. the results obtained during the follow-ups will allow the evaluation of the effectiveness of the treatment carried out. if this does not prove to be successful, through an evaluation of clinical and radiographic criteria, patients will be advised to undergo a second phase of treatment, in this case a surgical treatment of peri-implantitis, but which will no longer be part of the interventions carried out and documented in this study. patients for whom the unsatisfactory treatment was considered effective will be allocated to a periimplant support treatment program, which means that they will be advised to carry out maintenance consultations at the fmdup clinic with a specific and individualized periodicity in order to maintain the health of the periimplant tissues and the remaining oral cavity. the study will be carried out by the students of the specialization in periodontology and oral implantology 2021-2024 of the faculty of dental medicine of the university of porto (fmdup).

Eligibility criteria:
inclusion criteria: * at least 1 osseointegrated implant diagnosed with peri-implantitis (according to the new classification of periodontal and peri-implant diseases and conditions) and rehabilitated with screw-retained crown * patients of legal age (≥18 years old) exclusion criteria: * uncontrolled systemic pathologies, namely diabetes mellitus (hba1c \> 7% or \>53 mmol/mol) * pregnant or lactating patients * severe smoking (\>20 cigarettes/day) * systemic pathologies, medication or treatments that cause alterations in bone metabolism (for example: osteoporosis, bisphosphonates, radiotherapy of the head and neck) * patients who missed study control visits * patients who have received systemic antibiotic therapy in the last 2 months * patients with allergies to any of the components used in the study, namely to erythritol * implants that have previously undergone surgical treatment for peri-implantitis * implants with bone loss greater than 2/3 of their length and/or mobility
characterization and pathogenesis of aclf

Conditions: Liver Cirrhosis; Acute-On-Chronic Liver Failure; Portal Hypertension

Summary: this single-center prospective observational study aims at characterization of pathogenesis of aclf. there will be three different cohorts investigated with the main endpoint mortality in these groups. 1. sapient = sepsis aclf patients, to investigate the differences between aclf and sepsis in cirrhosis 2. proact = portal mediators as aclf targets, to assess portal venous biomarkers in patients receiving tips leading to aclf and identify potential treatment targets 3. elite = predictors of beneficial liver tx in acfl patients, to assess in aclf-patients receiving liver transplantation predictors of survival, which may improve selection of aclf-patients for liver transplantation secondary endpoints will be different in the three different cohorts and biological material will be collected for separate ancillary studies.


Eligibility criteria:
inclusion criteria: * liver cirrhosis exclusion criteria: * extrahepatic and metastatic malignancy, * refusal for participation * decision of attending phycisian
male partner involvement in the prevention of mtct of hiv

Conditions: HIV Infections

Summary: the study aims to invite male sexual partners to attend antenatal clinic with their pregnant partners to either acquire pregnancy information or undergo voluntary counselling and testing for hiv. to see if male sexual partner involvement will decrease sexual risk behaviour.

we will enrol 1000 pregnant women; recruited from antenatal clinic at khayelitsha midwive and obstetric unit (mou). community sensitization activities will be implemented in the catchment community to encourage male partner participation. at the booking visit all women will be offered antenatal care, hiv group education and vct as usual. thereafter women will be recruited to enrol into the study, after signing the consent form half of the cohort members will be randomly assigned to partner vct (group a) and half to partner pregnancy information (group b). men in group b will be offered vct at the second interview late in pregnancy. however, vct will be provided if requested by study participants at any stage of the study or if the female partner is hiv positive. women in group a will be given a written invitation to hand to their partners to encourage them to invite their partners to come to the antenatal clinic for vct. in group b, women will be given a written invitation to give to their partners to encourage their partners to attend a pregnancy information session at the antenatal clinic. vct will be offered again close to delivery for all women and men who were previously uninfected or of unknown status. for those found to be hiv-infected at a prior visit, cd4 and cd8 t-cell counts, viral load, and full blood count tests will be conducted. both women and men will be referred to the antiretroviral clinic where arv will be offered if appropriate and formula feeding (or exclusive breastfeeding) will be recommended. reasons for declining vct and data on sexual behaviour and violence will be sought at each visit.

Eligibility criteria:
inclusion criteria: * to be eligible for participation, a woman must be less than 30 weeks pregnant at enrolment. exclusion criteria: * women who are more than 30 weeks pregnant will be excluded.

Keywords: hiv mtct heterosexual behaviour sexual risk behaviour couple counselling voluntary counselling and testing hiv seronegativity
cannabis, hiv and mental processing systems

Conditions: HIV Infections; Cannabis

Summary: this study employs novel methods to identify key determinants and consequences of concurrent hiv infection and regular cannabis use. this study will acquire extensive phenotype data from peripheral and brain markers of immune activation, brain structure, and neuropsychological performance (np) in persons living with hiv (plwh) receiving combination anti-retroviral therapy (cart) (80 regular cannabis users and 80 non-users) and hiv uninfected (hiv-) controls (80 regular cannabis users and 80 non-users). this study will provide key insights into the effects of regular cannabis and hiv on peripheral and brain markers of immune function and np in plwh and hiv- controls. these insights are critical for cure strategies and ongoing hiv treatment initiatives.


Eligibility criteria:
inclusion criteria: 1. participants must be 18-70 years old. 2. plwh must have documented hiv infection for approximately 1 year, be on a cart regimen for approximately ≥3 months, and be virally well-controlled (\< 200 copies/ml). 3. hiv- controls must have confirmed hiv- serostatus. 4. participants must complete at least 9 years of education. 5. participants must be able to provide informed consent. 6. female participants must have a negative pregnancy test or written documentation of tubal ligation, hysterectomy, post-menopausal status, etc. and cannot be breastfeeding. 7. participants should have no contraindications to an mri scan. 8. participants should be willing to have cannabis use history confirmed via clinical interview and urine analysis . 9. all inclusion criteria at pi discretion. exclusion criteria: 1. history of neurological disorder (e.g., stroke, head injury with loss of consciousness for \>5 minutes, developmental learning disability, etc.). 2. uncontrolled major affective disorder; history of bipolar disorder or schizophrenia. major depression controlled with no hospitalizations or suicidal ideation in the past year is allowed. 3. current substance use disorder (sud) as defined by dsm-5 criteria besides cannabis use disorder (cud) (though a past sud \> 1 year before the time of study enrolment will be allowed). 4. currently prescribed anti-coagulants (only exclusionary if participant will engage in optional lp). 5. an allergy to lidocaine or similar anesthetic (only exclusionary if participant will engage in optional lp). 6. a history of a bleeding disorder (only exclusionary if participant will engage in optional lp). 7. claustrophobia or a pacemaker that would prevent magnetic resonance imaging (mri) scanning. 8. all exclusion criteria at pi discretion.
effect of biofeedback and functional electrical stimulation in children

Conditions: Hemiplegia

Summary: 40 children with hemiplegia cerebral palsy from both sex will be recruited from outpatient clinic of abo resh hospital ,their age ranged from 5-10 years

40 children with hemiplegia cerebral palsy from both sex will be recruited ,their age ranged from 5-10 years, treatment includes functional electrical nerve stimulation and biofeedback to assess their combined effect on upper limb function

Eligibility criteria:
inclusion criteria: * their age will range from 5 to 10 years. * spasticity grade range from 1+ to 2, according to modified ashworth scale (mas) (bohannon and smith, 2011). * their ul ability function will be at level ii according to manual ability classification system (macs) (penta et al., 2001). * they will be able to follow instructions. exclusion criteria: * loss of sensation * the presence of visual or auditory impairments. * musculoskeletal problems or fixed deformities in the upper extremities. * seizures. * surgical interference in upper limbs. * botulinum toxin injections in the last 6 months.
influenza burden assessment in the united states, july1997 - up to april 2009

Conditions: Influenza

Summary: the study will assess the burden of severe influenza outcomes by age, risk status, and influenza subtype, in order to create a profile of the burden of influenza-related morbidity and mortality in united states from july 1997 to april 2009.

this epidemiological study is a modelling of time series retrospectively extracted from multiple databases. data will be extracted from existing electronic healthcare databases.

Eligibility criteria:
inclusion criteria: * recorded in the us nis hospitalization data or the us national vital statistics system (nvss) mortality data with a pre-specified diagnostic code. exclusion criteria: * missing data in the following fields: age, primary discharge diagnosis, admission month (nis) /month of death (nvss), and status at discharge (alive / dead).

Keywords: united states burden of disease influenza
molecular, genetic, and genomic assessments from patients treated with rad001

Conditions: Metastatic Hormone Refractory Prostate Cancer

Summary: the purpose of this study is to look at the genetic changes that rad001 causes in prostate cancer cells and how those changes relate to patients' response to rad001 treatment.

this correlative science study will be a minimum risk assessment of tumor and plasma samples collected as part of a phase ii clinical trial of rad001 in patients with hrpc. prior to enrollment or at the time of signing consent in the phase ii trial, patients will be approached to participate in the correlative science study. patients who agree to participate will be assigned a separate study number which will be used to identify their molecular, genetic, genomic and biomarker assessments using the tumor and plasma samples. clinical outcome results from the accompanying phase ii trial will be used for correlative assessments in this study, however, results from this correlative science study will be kept separate from the assessments and reporting of the clinical trial.

Eligibility criteria:
inclusion criteria: * patients must be enrolled in the clinical study entitled: a single arm, phase ii study of rad001 in patients with metastatic, hormone-refractory prostate cancer at the time of enrollment onto this study.
anabolic therapy in postmenopausal osteoporosis

Conditions: Postmenopausal Osteoporosis

Summary: in this research study we want to learn more about the effect of two different fda-approved medications in the treatment of osteoporosis.


Eligibility criteria:
inclusion criteria: * postmenopausal women at high risk of fracture exclusion criteria: * prior therapy exclusions 1. current use or use in the past 12 months of oral bisphosphonates or denosumab 2. current use or use within the past 3 months of estrogens, serms, or calcitonin. 3. use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months 4. any current or previous use of romosozumab or strontium 5. current use or use within the past 3 years of teriparatide, abaloparatide, or any parenteral bisphosphonate. other exclusions 1. confirmed serum alkaline greater than 2 times the upper normal limit. 2. stage 4 or 5 chronic kidney disease (gfr less than 30) 3. hypercalcemia (ca greater than 10.5 mg/dl) 4. hypocalcemia (ca less than 8.8 mg/dl) 5. elevated blood pth (intact pth greater than 77 pg/ml) 6. serum 25-oh vitamin d less than 20 ng/ml 7. hct less than 32%. 8. history of malignancy (except basal cell carcinoma). 9. significant pulmonary disease 10. history of myocardial infarction or stroke within the preceding year. 11. history of unstable angina or transient ischemic attack in the past year. 12. current atrial fibrillation. 13. any health condition that, in the opinion of the study physician, significantly increases the risk of cardiovascular events. 14. major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. 15. excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. 16. uncontrolled eczema 17. congenital or acquired bone disease other than osteoporosis. 18. known sensitivity to denosumab or any of its excipients. 19. known sensitivity to romosozumab or any of its excipients. 20. history of osteonecrosis of the jaw, extensive dental work involving extraction or dental implants in the past 3 months, or extensive dental work planned in the upcoming 12 months.
evaluation of the attitude of pre menopausal women with breast cancer faced with the risk of fertility loss caused by chemotherapy

Conditions: Breast Cancer; Fertility

Summary: to evaluate the attitude of pre menopausal women with breast cancer faced with the risk of loss of fertility caused by chemotherapy using eortc's fertility questionnaire.

to characterize the attitude of pre menopausal patients with breast cancer regarding the risks of infertility based on the following variables: * age at diagnosis * number of children * will of having children * marital status * scholarity * period of time from the diagnosis * time of the last menstruation period * chemotherapy administration * clinical staging at the diagnosis * pathological evaluation * documentation of the cancer therapy

Eligibility criteria:
inclusion criteria: * women with age ≥ 18 and ≤ 40 * indication of (neo) adjuvant chemotherapy * prior chemotherapy treatment * patients with menstrual periods in the last 6 months * in use of contraceptive methods * without breast cancer recurrence * capacity to read and understand the informed consent exclusion criteria: * patients which received or with indication of definitive ovarian suppression (surgery and/or radiotherapy), except temporary pharmacological ovarian suppression * patients whom initiated chemotherapy treatment before entering the study * altered state of mind, dementia, or any other psychiatry problem that can interfere in the comprehension or interpretation of the informed consent. * previous diagnosis of infertility

Keywords: breast cancer fertility
effect of dash eating pattern on heart failure outcomes

Conditions: Heart Failure NYHA Class III

Summary: the objective of the study is to examine the effect of nutritional intake on cardiometabolic, inflammation, and physical function markers in advanced heart failure patients using a one-group pre-post test design feeding trial. effects on hemodynamic markers will be assessed in a subsample of patients with implanted hemodynamic monitoring devices (cardiomems). the pre-test condition is represented by participants' self-selected diet, and the post-test condition is represented by a prescribed dietary approaches to stop hypertension (dash) diet.


Eligibility criteria:
inclusion criteria: 1. 18+ years of age 2. english language literacy 3. diagnosis of hf ≥ 3 months 4. diagnosis of nyha class iii hf (historical assessment) 5. subjects must be stable on hf medication regimen for one month prior to study entry 6. at least 1 hf hospitalization within 24 months of enrollment 7. bnp \>200 pg/ml exclusion criteria: 1. subjects who have had an unplanned hf-related hospitalization within 2 months of enrollment 2. subjects with a glomerular filtration rate (gfr) \<25 ml/min who are nonresponsive to diuretic therapy or who are on chronic renal dialysis 3. subjects likely to undergo heart transplantation within 2 months of enrollment 4. subjects with severe conditions limiting 6-month survival 5. unavailability during scheduled data collection points 6. cognitive impairment

Keywords: nutrition dietary approaches to stop hypertension cardiometabolic outcomes pulmonary artery pressure cardiomems
comparison of engbd and ptgbd in acute suppurative cholecystitis

Conditions: Success Rate

Summary: comparison of engbd and ptgbd methods on clinical outcomes and the difficulty of cholecystectomy in later stage in patients with acute suppurative cholecystitis.

laparoscopic cholecystectomy was the standard surgical method for acute cholecystitis unless difficulty in resection due to acute inflammation, no improvement after supportive therapy, or early inability to tolerate cholecystectomy. in this setting, gallbladder drainage was needed. percutaneous transhepatic gallbladder drainage (ptgbd)was used as a first-line mitigation method, whose restrictions are contraindications and strong pain caused by puncture. endoscopic technique based on endoscopic retrograde cholangiopancreatography (ercp) had been made another alternative management for drainage. endoscopic drainage expanded the indications for drainage without reducing the technical success rate and clinical remission rate, especially less uncomfortable, which greatly improved the quality of life for patients. unfortunately, because of the difficult procedures and long learning curve, endoscopic gallbladder drainage can only be performed in some large endoscopic centers. despite a few prospective comparison of ptgbd and endoscopic ultrasound eus drainage studies so far, there is no prospective study comparing endoscopic naso-gallbladder drainage （engbd） and ptgbd, especially in its impacts while cholecystectomy. this study aim to observe clinical effects of engbd and ptgbd during the all stage of peri-cholecystectomy.

Eligibility criteria:
inclusion criteria: * acute suppurative cholecystitis * who can not tolerate or unsuitable for cholecystectomy exclusion criteria: * unwillingness or inability to consent for the study * coagulation dysfunction (inr\> 1.5) and low peripheral blood platelet count (\<50×10\^9 / l) or using anti-coagulation drugs * bile duct stones * prior surgery of bismuth ⅱ, roux-en-y and cholangiojejunostomy * preoperative coexistent diseases: acute pancreatitis, gi tract hemorrhage or perforation, severe liver disease(such as decompensated liver cirrhosis, liver failure and so on), septic shock * any malignant * pregnant women or breastfeeding

Keywords: ercp ptgbd engbd gallbladder drainage cholecystitis